ArticleIJTLD open2025
The effect of smart pillboxes on TB stigma among adults in a cluster-randomised TB treatment trial.
Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTB stigma has been shown to result in delayed health-seeking behaviours and treatment initiation. Few studies have quantitatively described stigma during treatment. As part of the TB Mate trial, we summarise TB stigma at treatment start and the effect of the intervention on stigma in follow-up.
methodsIn the TB Mate trial, we conducted a cluster-randomised trial in 18 primary health care facilities from three provinces in South Africa to evaluate the use of alarmed electronic pillboxes in drug-sensitive TB on treatment adherence. We administered a questionnaire, measuring five TB stigma domains, at baseline, 6 months, and 18 months. We conducted a sub-analysis of these stigma data.
resultsOverall, 2,469/2,657 adults with TB enrolled had a baseline stigma questionnaire. At baseline, reporting experience of stigma or internalised stigma was low (≤3%), whereas disclosure of TB status outside of the household was common (42.3%; 1,045/2,469). Prevalence of experiencing stigma remained low at the end of treatment. Disclosure increased at 6 months in the intervention (40%-64%) and standard of care arms (44.7%-56%), though was similar by arm (adjusted prevalence ratio 2.55 [95% confidence interval: 0.50-12.90]).
conclusionThe overall prevalence of TB stigma, in domains other than disclosure, in our study population was low. There was no evidence that stigma increased with use of an alarmed smart pillbox.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.